NCT00028158View on ClinicalTrials.gov

Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

October 31, 2003

Conditions
GliomaAstrocytomaGlioblastoma
Interventions
DRUG

G207, an oncolytic virus

Sponsors

Lead Sponsor

MediGene
All Listed Sponsors
lead

MediGene

INDUSTRY